ACR 43 is a concurrent resolution that declares March 2025 as Bleeding Disorders Awareness Month in California. The resolution collects legislative findings describing the health consequences of untreated bleeding disorders, notes the historic contamination of blood products in the 1980s, and highlights the role of federally recognized hemophilia treatment centers in reducing morbidity and mortality.
The measure is ceremonial: it does not appropriate funds, create regulatory duties, or change existing law. Its practical value is in elevating public awareness, giving state and local health partners a formal hook for outreach and education, and providing advocates and treatment centers an authoritative state-level statement they can cite when seeking attention, volunteers, or grants.
At a Glance
What It Does
ACR 43 is a legislative proclamation—a concurrent resolution—that designates March 2025 as Bleeding Disorders Awareness Month in California and records findings about inheritable bleeding disorders and past blood‑supply contamination. The only operational instruction is an administrative transmittal: the Chief Clerk of the Assembly is to send copies of the resolution to the author for distribution.
Who It Affects
The resolution primarily affects people with inheritable bleeding disorders, federally recognized hemophilia treatment centers, advocacy organizations, and public health entities that run outreach and education programs. Clinicians, hospital programs, and nonprofits are likely to use the designation as a planning and publicity tool.
Why It Matters
Although nonbinding, a formal legislative proclamation raises visibility, consolidates official findings that advocates can cite, and creates a timebound window for coordinated outreach, screening, fundraising, and referral campaigns—potentially increasing HTC referrals and public education in the short term.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
ACR 43 is a short, ceremonial measure: the Legislature adopts findings about inheritable bleeding disorders, recognizes the personal and public health harms that can follow untreated bleeding episodes, and calls for March 2025 to be observed in California as Bleeding Disorders Awareness Month. The text recites clinical consequences of bleeding events, references the 1980s contamination of blood products that infected many people with hemophilia, and states that visits to federally recognized hemophilia treatment centers reduce morbidity and mortality.
Because this is a concurrent resolution rather than a statute, it does not create enforceable rights, regulatory obligations, or funding streams. It also does not direct any state agency to change programs, expand services, or make payments.
Its mechanistic effect is limited: it memorializes legislative findings and provides an official recognition that state and local actors can reference.Practically speaking, stakeholders often use proclamations like this as a coordination device. Treatment centers, advocacy groups, and local public health departments can plan awareness events, educational campaigns, screening drives, or fundraising activities around the March designation and cite the Legislature’s findings in outreach materials and grant applications.
The resolution’s reference to federally recognized hemophilia treatment centers gives those centers rhetorical leverage but does not alter their funding or federal status.Administratively the only directive in the text is to have the Chief Clerk transmit copies of the resolution to the author for distribution. That keeps implementation decentralized: any follow‑through—events, messaging, or data collection—would depend on voluntary action by providers, nonprofits, and public health bodies rather than on a new state program or appropriation.
The Five Things You Need to Know
ACR 43 is a concurrent resolution—not a statute—so it proclaims March 2025 as Bleeding Disorders Awareness Month but creates no new legal obligations or funding.
The text contains legislative findings that document clinical harms from untreated bleeding episodes and notes past contamination of blood products in the 1980s.
The resolution explicitly cites federally recognized hemophilia treatment centers and asserts that visits to those centers reduce morbidity and mortality.
The only operational step the resolution directs is administrative: the Chief Clerk of the Assembly must transmit copies of the resolution to the author for distribution.
ACR 43’s impact depends entirely on voluntary follow‑through by treatment centers, advocacy groups, and public health agencies—it does not require state agencies to act or report.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Documenting the problem and historical harms
This opening portion collects the Legislature’s factual statements: it identifies inheritable bleeding disorders by name, summarizes the medical consequences of uncontrolled bleeding (joint damage, internal organ injury, disability, death), and recalls that many people with hemophilia were infected with HIV and hepatitis C in the 1980s due to contaminated blood products. Those findings serve two purposes: they frame the public‑health rationale for recognition and provide advocates a concise, state‑endorsed statement of the historical and clinical context.
Proclamation of Bleeding Disorders Awareness Month
This is the operative recognition: the Legislature pauses to proclaim March 2025 as Bleeding Disorders Awareness Month. As a concurrent resolution, the clause expresses legislative sentiment rather than command; it creates a symbolic observance intended to promote awareness, community building, and public engagement. The clause does not request or appropriate funds, nor does it impose programmatic duties on state agencies.
Administrative distribution of the resolution
The final provision instructs the Chief Clerk of the Assembly to transmit copies of the resolution to the author for appropriate distribution. Practically, that is the only required administrative action: it ensures the text reaches the sponsoring office and, from there, can be circulated to stakeholders, posted publicly, or used in outreach materials. There is no statutory follow‑up, reporting requirement, or implementation timeline attached.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with inheritable bleeding disorders: The designation raises public and clinical attention that can translate into more referrals, greater public awareness, and potentially earlier diagnosis or treatment during the awareness window.
- Federally recognized hemophilia treatment centers (HTCs): HTCs can leverage the Legislature’s findings and the March designation for outreach, partnership building, and grant or fundraising materials.
- Advocacy organizations and patient groups: State recognition provides a cited authority to support awareness events, volunteer recruitment, and fundraising appeals.
- Public health and local health departments: The proclamation gives departments a timely framing device for campaigns, educational materials, and community engagement around bleeding disorders.
Who Bears the Cost
- The State Legislature: Minimal direct cost—the resolution asks the Legislature to pause and the Chief Clerk to transmit copies, which consumes time and staff resources.
- Treatment centers and nonprofits: Expectation and demand to run awareness events may create unfunded workload and administrative costs for HTCs and advocacy groups.
- State public health offices: The designation may increase inquiries or requests for materials without associated budgetary support to expand services.
- Health care providers and clinics: A short‑term uptick in referrals or diagnostic testing could impose operational strain if community outreach substantially increases demand.
Key Issues
The Core Tension
The central tension is symbolic recognition versus substantive change: the resolution aims to raise awareness and legitimize advocacy, but it offers no funding, mandates, or programmatic fixes—leaving advocates and providers to translate symbolism into concrete services with their own resources.
The resolution sits at the intersection of symbolism and practical public‑health need, which creates several implementation questions. First, proclamations can raise expectations: patients and advocates may read the designation as a promise of increased services or funding, but the text contains no appropriation or program mandate.
That gap can generate frustration if stakeholders expect state support that the resolution does not provide.
Second, the measure’s focus on a single month creates a timebound opportunity but does not address continuity of care or longer‑term system gaps—such as access disparities, reimbursement issues, or workforce shortages at treatment centers. Third, by referencing federally recognized hemophilia treatment centers, the resolution highlights a care model that reduces harm, yet it imposes no change to HTC capacity or certification; readers could mistakenly infer that the state will expand or fund those centers.
Finally, the historical finding about contaminated blood products acknowledges past harms but stops short of proposing remedies or compensation, which could revive policy debates without providing a legislative pathway to address them.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.